BioSpace News Archive

More than 1.62 million instrumented spinal implants occur every year in the US. Well, that’s the tally if we consider hundreds of CPT and ICD codes.

Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has finalized a new Cooperative Research and Development Agreement (CRADA) with Walter Reed Army Institute of Research (WRAIR).

GlaxoSmithKline – This year, the #TUMSBingoSweepstakes is the BIG GAME within the BIG GAME and takes place on a day known for indulging in heartburn-inducing food and fans experiencing TUMSworthy moments.

Company plans to advance its VMT01 program into Phase 1 imaging study, to be followed by Phase 1/2a therapy study for the treatment of metastatic melanoma

Agilent Technologies Inc. (NYSE: A) today announced it has won a judgement in federal court for patent infringement and trade secret misappropriation against Shanghai-based J&X Technologies.

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics (“AffyXell”), the joint venture with Daewoong Pharmaceutical (“Daewoong”), has closed a Series A venture capital investment of $7.3 million to further develop its pipeline of next generation cell and gene therapies.

SIFI, a leading ophthalmic company, announced today the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers.

Intramuscular injection PLEGRIDY (peginterferon beta-1a) is now approved in the U.S. and the European Union, offering individuals with relapsing multiple sclerosis (MS) a treatment option with significantly reduced injection site reactions PLEGRIDY has a well-characterized safety and efficacy profile with a proven ability to reduce relapses and delay disability progression

Arcutis today announced positive topline results from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential topical treatment for plaque psoriasis.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, announced the appointment of Bettina Maunz as Chief People Officer.